Results 51 to 60 of about 809 (101)

EIDD-1931 Treatment Tweaks CYP3A4 and CYP2C8 in Arthritic Rats to Expedite Drug Interaction: Implication in Oral Therapy of Molnupiravir [PDF]

ACS Omega
Debaraj Mukherjee, , Utpal Nandi
exaly   +2 more sources

Boesenbergia rotunda–Derived Phytochemicals as Potent Inhibitors of SARS‐CoV‐2 Papain–Like Protease (PLpro): Insights From Molecular Docking and Dynamic Simulation

Scientifica, Volume 2026, Issue 1, 2026.
The papain‐like protease (PLpro) of SARS‐CoV‐2 plays fundamental roles in its replication, and its mechanistic inhibition can impede the virus’s replication and infection. Most Plpro inhibitors identified thus far are chemically synthesized and subject to numerous restrictions regarding stability and adverse side effects.
Dhrubo Ahmed Khan, Mohammad Ashik Sheikh, Raihan Rahman Imon, Md. Imtiaz, Shamin Ahmed, Harasit Gharami, Ryan V. Labana, Tajudeen O. Jimoh, Anand Gaurav, Maria L. Pereira, Muhammad Nawaz, Julieta Z. Dungca, Md. Nazmul Hasan, Manik Ghosh, Veeranoot Nissapatorn, Nidhi Chaudhary   +15 more
wiley   +1 more source

Efficacy of Oseltamivir Against Seasonal Influenza H1N1 and the Efficacy of a Novel Combination Treatment In Vitro and In Vivo in Mouse Studies

Influenza and Other Respiratory Viruses, Volume 19, Issue 10, October 2025.
ABSTRACT Background Influenza surveillance and drug resistance testing have always been central to clinical efforts. Therefore, researching the virus characteristics and antiviral drugs is essential. Method The HA and NA activities were assessed in influenza strains, and mutations were identified through gene sequencing.
Danlei Liu, Ka‐Yi Leung, Ruiqi Zhang, Hoi‐Yan Lam, Yujing Fan, Xiaochun Xie, Wan‐Mui Chan, Kelvin Kai‐Wang To, Kwok‐Hung Chan, Ivan Fan‐Ngai Hung   +9 more
wiley   +1 more source

COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples

British Journal of Clinical Pharmacology, Volume 90, Issue 9, Page 2137-2158, September 2024.
Aim Understanding how COVID‐19 impacts the expression of clinically relevant drug metabolizing enzymes and membrane transporters (DMETs) is vital for addressing potential safety and efficacy concerns related to systemic and peripheral drug concentrations.
Chukwunonso K. Nwabufo, Jessica Luc, Allison McGeer, Jeremy Alexander Hirota, Samira Mubareka, Andrew C. Doxey, Theo J. Moraes   +6 more
wiley   +1 more source

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis

Journal of Microbiology, Immunology and Infection
Background: The majority of available data on molnupiravir come from an unvaccinated COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence from recent randomized controlled trials (RCTs) as well as observational studies ...
Huzaifa Ahmad Cheema, Saleha Abdul Rab, Momina Butt, Uzair Jafar, Abia Shahid, Aqeeb Ur Rehman, Ka Yiu Lee, Syeda Sahra, Ranjit Sah   +8 more
doaj   +1 more source

Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study

Journal of Medical Virology, Volume 96, Issue 5, May 2024.
Abstract Molnupiravir, an oral direct‐acting antiviral effective in vitro against SARS‐CoV‐2, has been largely employed during the COVID‐19 pandemic, since December 2021. After marketing and widespread usage, a progressive increase in SARS‐CoV‐2 lineages characterized by a higher transition/transversion ratio, a characteristic signature of molnupiravir
Cesare Ernesto Maria Gruber, Fabio Giovanni Tucci, Emanuela Giombini, Valentina Mazzotta, Pietro Giorgio Spezia, Martina Rueca, Ilaria Mastrorosa, Lavinia Fabeni, Giulia Berno, Ornella Butera, Silvia Rosati, Eliana Specchiarello, Fabrizio Carletti, Daniele Focosi, Emanuele Nicastri, Enrico Girardi, Andrea Antinori, Fabrizio Maggi   +17 more
wiley   +1 more source

Molnupiravir: Mechanism of action, clinical, and translational science

Clinical and Translational Science, Volume 17, Issue 2, February 2024.
Abstract Molnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP). NHC‐TP serves as a competitive substrate for viral RNA‐dependent RNA polymerase (RdRp), which results in an accumulation ...
Brian M. Maas, Julie Strizki, Randy R. Miller, Sushma Kumar, Michelle Brown, Matthew G. Johnson, Mickie Cheng, Carisa De Anda, Matthew L. Rizk, Julie A. Stone   +9 more
wiley   +1 more source

New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses

Antiviral Research
The spread of COVID-19 continues due to genetic variation in SARS-CoV-2. Highly mutated variants of SARS-CoV-2 have an increased transmissibility and immune evasion. Due to the emergence of various new variants of the virus, there is an urgent need to develop broadly effective specific drugs for therapeutic strategies for the prevention and treatment ...
Andrei E. Siniavin, Vladimir A. Gushchin, Natal'ya S. Shastina, Elizaveta S. Darnotuk, Sergey I. Luyksaar, Leonid I. Russu, Anna M. Inshakova, Elena V. Shidlovskaya, Daria V. Vasina, Nadezhda A. Kuznetsova, Daria M. Savina, Ilya D. Zorkov, Inna V. Dolzhikova, Anna B. Sheremet, Denis Y. Logunov, Nailya A. Zigangirova, Alexander L. Gintsburg   +16 more
openaire   +2 more sources

2025 ACVIM Forum Research Abstract Program

Journal of Veterinary Internal Medicine, Volume 39, Issue 6, November/December 2025.
wiley   +1 more source

RESEARCH COMMUNICATIONS OF THE 34th ECVIM‐CA CONGRESS

Journal of Veterinary Internal Medicine, Volume 38, Issue 6, Page 3537-3694, November/December 2024.
wiley   +1 more source